Limited utility of plasma M30 in discriminating non-alcoholic steatohepatitis from steatosis - A comparison with routine biochemical markers

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Chan, Wah Kheong ^a   Sthaneshwar, Pavai ^a   Mustapha, Nik Raihan Nik ^b   Mahadeva, Sanjiv ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b Alor Setar Hospital Malaysia   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYTOKERATIN 18; GAMMA GLUTAMYLTRANSFERASE; BIOLOGICAL MARKER; M30 CYTOKERATIN-18 PEPTIDE, HUMAN; PEPTIDE FRAGMENT;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASIAN; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE CLASSIFICATION; FATTY LIVER; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; AGED; BLOOD; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; LIVER; METABOLISM; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY;

ADULT; AGED; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; FATTY LIVER; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; KERATIN-18; LIVER; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PEPTIDE FRAGMENTS;

EID: 84906972045     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105903     Document Type: Article

References (18)

1. Chan WK, Goh KL (2013) Epidemiology of a fast-emerging disease in the Asia-Pacific region: non-alcoholic fatty liver disease. Hepatol Int 7:65-71.
2. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, et al. (2006) Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44:865-73.
3. Sanyal AJ, Banas C, Sargeant C, Luketic VA, Sterling RK, et al. (2006) Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 43:682-9.
4. Piccinino F, Sagnelli E, Pasquale G, Giusti G (1986) Complications following percutaneous liver biopsy. A multicentre retrospective study on 68, 276 biopsies. Journal of hepatology 2:165-73.
5. Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, et al. (2003) Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125:437-43.
6. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, et al. (2006) In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 44:27-33.
7. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, et al. (2009) Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 50:1072-8.
8. Diab DL, Yerian L, Schauer P, Kashyap SR, Lopez R, et al. (2008) Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 6:1249-54.
9. Tamimi TI, Elgouhari HM, Alkhouri N, Yerian LM, Berk MP, et al. (2011) An apoptosis panel for nonalcoholic steatohepatitis diagnosis. Journal of hepatology 54:1224-9.
10. Yilmaz Y, Dolar E, Ulukaya E, Akgoz S, Keskin M, et al. (2007) Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World journal of gastroenterology: WJG 13:837-44.
11. Shen J, Chan HL, Wong GL, Choi PC, Chan AW, et al. (2012) Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. Journal of hepatology 56:1363-70.
12. Shen J, Chan HL, Wong GL, Chan AW, Choi PC, et al. (2012) Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers. Alimentary pharmacology & therapeutics 36:1057-66.
13. Cusi K, Chang Z, Harrison S, Lomonaco R, Bril F, et al. (2014) Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. Journal of hepatology 60:167-74.
14. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, et al. (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55:2005-23.
15. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313-21.
16. Suzuki A, Lymp J, Sauver JS, Angulo P, Lindor K (2006) Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis. Liver international: official journal of the International Association for the Study of the Liver 26:1209-16.
17. Younossi ZM, Page S, Rafiq N, Birerdinc A, Stepanova M, et al. (2011) A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obes Surg 21:431-9.
18. Yilmaz Y, Eren F (2012) Identification of a support vector machine-based biomarker panel with high sensitivity and specificity for nonalcoholic steatohepatitis. Clin Chim Acta 24:154-7.